Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25695
Abstract: 1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369: 111-121. 2. Nagendra S, Meyerson H, Skallerud G, et al. Leukemias resembling… read more here.
Keywords: acute promyelocytic; myeloid leukemia; promyelocytic leukemia; acute myeloid ... See more keywords
A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.26041
Abstract: Twice‐weekly carfilzomib with lenalidomide‐dexamethasone (Rd) is an effective regimen for newly diagnosed multiple myeloma (NDMM). Here we evaluated once‐weekly carfilzomib with Rd (once‐weekly KRd) in NDMM patients. The NDMM patients were enrolled regardless of transplant… read more here.
Keywords: newly diagnosed; multiple myeloma; weekly carfilzomib; carfilzomib ... See more keywords
Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen‐induced hepatotoxicity in mice
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.21877
Abstract: Overdose of acetaminophen (APAP) is often associated with hepatotoxicity. Carfilzomib (CFZ) shows multiple pharmacological activities including anti‐inflammatory potential. Therefore, this study was undertaken to evaluate the possible therapeutic effects of CFZ against APAP‐induced hepatotoxicity. Hepatotoxicity… read more here.
Keywords: induced hepatotoxicity; cfz post; hepatotoxicity; therapeutic potential ... See more keywords
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-021-04407-0
Abstract: Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical… read more here.
Keywords: clinical trial; asian patients; treatment; outside clinical ... See more keywords
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2018.02.008
Abstract: Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids. Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence… read more here.
Keywords: multiple myeloma; toxicity profile; carfilzomib; efficacy ... See more keywords
Carfilzomib-induced thrombotic microangiopathy: A case based review.
Sign Up to like & getrecommendations! Published in 2020 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2020.07.001
Abstract: Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and… read more here.
Keywords: treatment; case; carfilzomib induced; carfilzomib ... See more keywords
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
Sign Up to like & getrecommendations! Published in 2017 at "Blood Cancer Journal"
DOI: 10.1038/bcj.2017.31
Abstract: Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was based on results from the randomized, phase… read more here.
Keywords: treatment; dexamethasone; carfilzomib; lenalidomide dexamethasone ... See more keywords
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2017.122
Abstract: Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or… read more here.
Keywords: endeavor; carfilzomib based; multiple myeloma; stem cell ... See more keywords
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01141-4
Abstract: Carfilzomib (CFZ) improves survival in relapsed/refractory multiple myeloma but is associated with cardiovascular adverse events (CVAEs). We prospectively investigated the effect of CFZ on endothelial function and associations with CVAEs. Forty-eight patients treated with Kd… read more here.
Keywords: cfz; recovery; fmd; proteasome activity ... See more keywords
A prospective, iterative, adaptive trial of carfilzomib‐based desensitization
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Transplantation"
DOI: 10.1111/ajt.15613
Abstract: Proteasome inhibitor–based strategies hold promise in transplant but have yielded varying results. Carfilzomib, a second‐generation proteasome inhibitor, may possess advantages over bortezomib, the first‐generation proteasome inhibitors. The purpose of this study was to evaluate the… read more here.
Keywords: adaptive trial; iterative adaptive; based desensitization; desensitization ... See more keywords
Infection risk with carfilzomib in multiple myeloma: a systematic review and meta‐analysis of randomised controlled trials
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16735
Abstract: Carfilzomib is an irreversible epoxyketone-based proteasome inhibitor (PI) that is specific for the chymotrypsin-like active site of 20S proteasome. In 2012, carfilzomib was first approved for the treatment of relapsed/refractory multiple myeloma (MM). It has… read more here.
Keywords: risk; analysis; infection; serious infections ... See more keywords